The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 01, 2020
Filed:
Jan. 08, 2018
Duke University, Durham, NC (US);
Triad National Security, Llc, Los Alamos, NM (US);
The Trustees of the University of Pennsylvania, Philadelphia, PA (US);
Trustees of Boston University, Boston, MA (US);
The Government of the United States of America As Represented BY the Secretary of the Department of Health and Human Services, Rockville, MD (US);
The Board of Trustees of the Leland Stanford Junior University, Palo Alto, CA (US);
Barton F. Haynes, Durham, NC (US);
Hua-Xin Liao, Durham, NC (US);
Rebecca M. Lynch, Rockville, MD (US);
Tongqing Zhou, Rockville, MD (US);
Feng Gao, Durham, NC (US);
Scott Boyd, Palo Alto, CA (US);
George M. Shaw, Philadelphia, PA (US);
Beatrice H. Hahn, Philadelphia, PA (US);
Thomas B. Kepler, Boston, MA (US);
Bette T. Korber, Los Alamos, NM (US);
Peter Kwong, Rockville, MD (US);
John R. Mascola, Rockville, MD (US);
Duke University, Durham, NC (US);
Triad National Security, LLC, Los Alamos, NM (US);
The Trustees of The University of Pennsylvania, Philadelphia, PA (US);
Trustees of Boston University, Boston, MA (US);
The Government of The United States of America as Represented by the Secretary of the Department of Health and Human Services, Rockville, MD (US);
The Board of Trustees of the Leland Stanford Junior University, Palo Alto, CA (US);
Abstract
The present invention relates, in general, to HIV-1 and, in particular, to broadly neutralizing HIV-1 antibodies, and to HIV-1 immunogens and to methods of using such immunogens to induce the production of broadly neutralizing HIV-1 antibodies in a subject (e.g., a human).